Clinical efficacy of camrelizumab combined with lunvatinib or bevacizumab in the treatment of hepatocellular carcinoma

Clinical efficacy of camrelizumab combined with lunvatinib or bevacizumab in the treatment of hepatocellular carcinoma

Objective To evaluate the clinical efficacy of camrelizumab combined with lunvatinib or bevacizumab in the treatment of hepatocellular carcinoma （HCC）. Methods Clinical data of 60 patients with HCC were retrospectively analyzed. All patients were divided into group A （camrelizumab combined with lunv...

Full description

Bibliographic Details
Main Author:	Lai Fengting, Liu Huaqiang, Cai Yongguang
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of New Medicine 2023-06-01
Series:	Xin yixue
Subjects:	\|hepatocellular carcinoma\|camrelizumab\|bevaczumab\|lunvatinib\|tumor marker
Online Access:	https://www.xinyixue.cn/fileup/0253-9802/PDF/1689304294501-883737356.pdf

Similar Items

RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
by: Qing Yang, et al.
Published: (2023-03-01)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
by: Qinqin Liu, et al.
Published: (2021-10-01)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
by: Juan Wu, et al.
Published: (2023-10-01)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
by: Juanfang Liu, et al.
Published: (2021-10-01)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
by: Xiaomi Li, et al.
Published: (2023-08-01)

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation
by: Yin L, et al.
Published: (2022-09-01)

Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report
by: Zhihong Chen, et al.
Published: (2023-01-01)

Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery
by: Xudan Wang, et al.
Published: (2023-12-01)

Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
by: Ran You, et al.
Published: (2022-08-01)

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression
by: Zhenggang Ren, et al.
Published: (2021-06-01)

Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
by: Bo Sun, et al.
Published: (2022-09-01)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
by: Qi Li, et al.
Published: (2022-02-01)

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
by: Jinpeng Li, et al.
Published: (2023-07-01)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
by: Xin Li, et al.
Published: (2022-10-01)

Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China
by: Haonan Liu, et al.
Published: (2022-09-01)

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review
by: Xin-Liang Liu, et al.
Published: (2024-03-01)

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
by: Xiao Y, et al.
Published: (2023-11-01)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
by: Hideki Iwamoto, et al.
Published: (2022-07-01)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
by: Fei Chen, et al.
Published: (2022-08-01)

Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study
by: Yun Huang, et al.
Published: (2021-08-01)

The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study
by: Yin GQ, et al.
Published: (2022-06-01)

Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases
by: Tianxing Dai, et al.
Published: (2022-06-01)

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
by: Feng Wang, et al.
Published: (2020-05-01)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
by: Hong Zhou, et al.
Published: (2021-11-01)

Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
by: Qing-Yu Xie, et al.
Published: (2022-02-01)

Successful treatment of recurrent sarcomatous choledochal carcinoma with camrelizumab and apatinib
by: Shilei Li
Published: (2023-11-01)

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
by: Yunyan Mo, et al.
Published: (2024-01-01)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
by: Hongfu Cai, et al.
Published: (2021-11-01)

Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial
by: Yue Hu, et al.
Published: (2020-08-01)

Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer
by: Dou Zhang, et al.
Published: (2024-01-01)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
by: Kunlun Wang, et al.
Published: (2020-10-01)

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
by: Peng Yang, et al.
Published: (2021-11-01)

First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study
by: Xiaofen Li, et al.
Published: (2022-09-01)

Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study
by: Ya Gao, et al.
Published: (2023-11-01)

Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)
by: Yang Yang, et al.
Published: (2022-05-01)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
by: Yusheng Guo, et al.
Published: (2022-03-01)

A Correlation Evaluation Between the Peripheral Blood Index and the Prognosis of Advanced Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab
by: Shang H, et al.
Published: (2024-03-01)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
by: Rui-Qin Zhou, et al.
Published: (2023-05-01)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
by: Jun Ni, et al.
Published: (2023-04-01)

Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis
by: Min Chen, et al.
Published: (2024-01-01)